Risk factors for infuenza virus related severe lower respiratory tract infection in children

Basit Öğe Kaydı
dc.contributor.authorEşki A.
dc.contributor.authorÖztürk G.K.
dc.contributor.authorGülen F.
dc.contributor.authorÇiçek C.
dc.contributor.authorDemir E.
dc.date.accessioned2021-05-03T20:48:13Z
dc.date.available2021-05-03T20:48:13Z
dc.date.issued2019
dc.description.abstractBackground: Influenza virus is one of the most common respiratory pathogens for all age groups and may cause seasonal outbreaks. Our aim was to identify risk groups and factors associated with severe clinical course including mortality in children with influenza-related lower respiratory tract infection (LRTI). Methods: We conducted a retrospective study in children hospitalized with influenza virus LRTI from 2008 to 2018. Data on demographic features, influenza type, viral coinfection, primary and secondary bacterial infections (SBIs), time of onset of antiviral treatment, comorbidities, hospitalization length, pediatric intensive care unit admission/invasive mechanical ventilation (IMV) need and mortality were collected from medical records. Results: There were 280 patients hospitalized with LRTI and median hospitalization length was 9 days. Congenital heart disease, neuromuscular disease, SBIs and late-onset antiviral treatment were independent risk factors for prolonged hospital stay (P < 0.05). Pediatric intensive care unit admission was present in 20.4% (57) of the patients and 17.1% (48) of all patients required IMV. SBIs, lymphopenia, neutrophilia, immunosuppression and human bocavirus coinfection were independent risk factors for IMV support (P < 0.05). Eighteen patients died and immunosuppression, lymphopenia and SBIs were independent risk factors for mortality (P < 0.05). Conclusions: Presence of comorbidity, SBIs, neutrophilia and lymphopenia at admission identified as risk factors for severe influenza infections including need for IMV and death. Although several studies showed that antiviral treatment reduce hospitalization, complications and mortality, there is a lack of prospective trials and patients for antiviral therapy should be carefully chosen by the clinician. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.identifier.doi10.1097/INF.0000000000002447en_US
dc.identifier.endpage1095en_US
dc.identifier.issn0891-3668
dc.identifier.issue11en_US
dc.identifier.pmid31469782en_US
dc.identifier.scopus2-s2.0-85073584262en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1090en_US
dc.identifier.urihttps://doi.org/10.1097/INF.0000000000002447
dc.identifier.urihttps://hdl.handle.net/11454/70800
dc.identifier.volume38en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.relation.ispartofPediatric Infectious Disease Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChildrenen_US
dc.subjectInfluenzaen_US
dc.subjectMortalityen_US
dc.subjectSevere pulmonary infectionen_US
dc.titleRisk factors for infuenza virus related severe lower respiratory tract infection in childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu